FDA: New warning needed for Chantix

February 3, 2008

The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.

The agency said it appears increasingly likely that there may be an association between the drug, marketed by Pfizer under the name Chantix, and serious neuropsychiatric symptoms including agitation, depression, suicidal thoughts and actual suicidal behavior.

The FDA has requested that Pfizer elevate the prominence of this safety information to the warnings and precautions section of the Chantix prescribing information.

"Chantix has proven to be effective in smokers motivated to quit, but patients and healthcare professionals need the latest safety information to make an informed decision regarding whether or not to use this product," the FDA's Dr. Bob Rappaport said in a release. "While Chantix has demonstrated clear evidence of efficacy, it is important to consider these safety concerns and alert the public about these risks.

Chantix was approved by FDA in May 2006 as a smoking cessation drug.

Copyright 2008 by United Press International

Explore further: Stop-smoking drug Chantix may carry heart risks, FDA warns

Related Stories

Stop-smoking drug Chantix may carry heart risks, FDA warns

December 13, 2012

(HealthDay)—People who take the prescription quit-smoking drug Chantix may be at higher risk for cardiovascular problems, and doctors should weigh the risks of the drug against it benefits, the U.S. Food and Drug Administration ...

Safety advocates seek stronger warnings on Chantix (Update)

October 8, 2014

Public safety advocates are asking the federal government to strengthen warnings on Pfizer's anti-smoking drug Chantix, even as the drugmaker prepares to argue that a bold-letter warning about psychiatric problems should ...

New FDA label bolsters safety case for Chantix

September 24, 2014

New government-approved labeling on Pfizer's drug Chantix suggests that the anti-smoking medication may not carry the risks of suicidal behavior that first earned it the Food and Drug Administration's strongest warning more ...

FDA reviews psychiatric side effects of Chantix

April 25, 2014

The U.S. Food and Drug Administration announced Friday it will convene a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer's anti-smoking drug Chantix.

Testing anti-drinking drug with help of a fake bar

January 1, 2015

The tequila sure looks real, so do the beer taps. Inside the hospital at the National Institutes of Health, researchers are testing a possible new treatment to help heavy drinkers cut back—using a replica of a fully stocked ...

Recommended for you

Universal flu vaccine designed by scientists

September 30, 2016

An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.